Metformin reduces abortion in pregnant women with polycystic ovary syndrome

References

• Asuncion M, Calvo R M, San Millan J L, Sancho J, Avila S, Escobar-Morreale H F. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab 2000; 85: 2434–2438
   PubMed Web of Science ®Google Scholar
• Knochenhauer E S, Key T J, Kahsar-Miller M, Waggoner W, Boots L R, Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab 1998; 83: 3078–3082
   PubMed Web of Science ®Google Scholar
• The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004; 19: 41–47
   PubMed Web of Science ®Google Scholar
• Balen A H, Tan S L, MacDougall J, Jacobs H S. Miscarriage rates following in-vitro fertilization are increased in women with polycystic ovaries and reduced by pituitary desensitization with buserelin. Hum Reprod 1993; 8: 959–964
   PubMed Web of Science ®Google Scholar
• Gray R H, Wu L Y. Subfertility and risk of spontaneous abortion. Am J Public Health 2000; 90: 1452–1454
   PubMed Web of Science ®Google Scholar
• Regan L, Owen E J, Jacobs H S. Hypersecretion of luteinising hormone, infertility, and miscarriage. Lancet 1990; 336: 1141–1144
   PubMed Web of Science ®Google Scholar
• Watson H, Kiddy D S, Hamilton-Fairley D, Scanlon M J, Barnard C, Collins W P, Bonney R C, Franks S. Hypersecretion of luteinizing hormone and ovarian steroids in women with recurrent early miscarriage. Hum Reprod 1993; 8: 829–833
   PubMedGoogle Scholar
• Homburg R, Armar N A, Eshel A, Adams J, Jacobs H S. Influence of serum luteinising hormone concentrations on ovulation, conception, and early pregnancy loss in polycystic ovary syndrome. Br Med J 1988; 297: 1024–1026
   PubMed Web of Science ®Google Scholar
• Clifford K, Rai R, Watson H, Franks S, Regan L. Does suppressing luteinising hormone secretion reduce the miscarriage rate? Results of a randomised controlled trial. Br Med J 1996; 312: 1508–1511
   PubMed Web of Science ®Google Scholar
• Fedorcsak P, Storeng R, Dale P O, Tanbo T, Abyholm T. Obesity is a risk factor for early pregnancy loss after IVF or ICSI. Acta Obstet Gynecol Scand 2000; 79: 43–48
   PubMed Web of Science ®Google Scholar
• Okon M A, Laird S M, Tuckerman E M, Li T C. Serum androgen levels in women who have recurrent miscarriages and their correlation with markers of endometrial function. Fertil Steril 1998; 69: 682–690
   PubMed Web of Science ®Google Scholar
• Tulppala M, Stenman U H, Cacciatore B, Ylikorkala O. Polycystic ovaries and levels of gonadotrophins and androgens in recurrent miscarriage: prospective study in 50 women. Br J Obstet Gynaecol 1993; 100: 348–352
   PubMedGoogle Scholar
• Glueck C J, Wang P, Fontaine R, Tracy T, Sieve-Smith L. Metformin-induced resumption of normal menses in 39 of 43 (91%) previously amenorrheic women with the polycystic ovary syndrome. Metabolism 1999; 48: 511–519
   PubMed Web of Science ®Google Scholar
• Glueck C J, Kupferminc M J, Fontaine R N, Wang P, Weksler B B, Eldor A. Genetic hypofibrinolysis in complicated pregnancies. Obstet Gynecol 2001; 97: 44–48
   PubMed Web of Science ®Google Scholar
• Jakubowicz D J, Iuorno M J, Jakubowicz S, Roberts K A, Nestler J E. Effects of metformin on early pregnancy loss in the polycystic ovary syndrome. J Clin Endocrinol Metab 2002; 87: 524–529
   PubMed Web of Science ®Google Scholar
• Palomba S, Russo T, Orio F, Jr, Falbo A, Manguso F, Cascella T, Tolino A, Carmina E, Colao A, Zullo F. Uterine effects of metformin administration in anovulatory women with polycystic ovary syndrome. Hum Reprod 2006; 21: 457–465
   PubMed Web of Science ®Google Scholar
• Coetzee E J, Jackson W P. Oral hypoglycaemics in the first trimester and fetal outcome. S Afr Med J 1984; 65: 635–637
   PubMed Web of Science ®Google Scholar
• Sarlis N J, Weil S J, Nelson L M. Administration of metformin to a diabetic woman with extreme hyperandrogenemia of nontumoral origin: management of infertility and prevention of inadvertent masculinization of a female fetus. J Clin Endocrinol Metab 1999; 84: 1510–1512
   Google Scholar
• Jakubowicz D J, Seppala M, Jakubowicz S, Rodriguez-Armas O, Rivas-Santiago A, Koistinen H, Koistinen R, Nestler J E. Insulin reduction with metformin increases luteal phase serum glycodelin and insulin-like growth factor-binding protein 1 concentrations and enhances uterine vascularity and blood flow in the polycystic ovary syndrome. J Clin Endocrinol Metab 2001; 86: 1126–1133
   PubMed Web of Science ®Google Scholar
• Jakubowicz D J, Essah P A, Seppala M, Jakubowicz S, Baillargeon J P, Koistinen R, Nestler J E. Reduced serum glycodelin and insulin-like growth factor-binding protein-1 in women with polycystic ovary syndrome during first trimester of pregnancy. J Clin Endocrinol Metab 2004; 89: 833–839
   PubMed Web of Science ®Google Scholar
• Bolton A E, Pockley A G, Clough K J, Mowles E A, Stoker R J, Westwood O M, Chapman M G. Identification of placental protein 14 as an immunosuppressive factor in human reproduction. Lancet 1987; 1: 593–595
   PubMed Web of Science ®Google Scholar
• Okamoto N, Uchida A, Takakura K, Kariya Y, Kanzaki H, Riittinen L, Koistinen R, Seppala M, Mori T. Suppression by human placental protein 14 of natural killer cell activity. Am J Reprod Immunol 1991; 26: 137–142
   PubMed Web of Science ®Google Scholar
• Giudice L C, Mark S P, Irwin J C. Paracrine actions of insulin-like growth factors and IGF binding protein-1 in non-pregnant human endometrium and at the decidual–trophoblast interface. J Reprod Immunol 1998; 39: 133–148
   PubMed Web of Science ®Google Scholar
• Jones J I, Gockerman A, Busby W H, Jr, Wright G, Clemmons D R. Insulin-like growth factor binding protein 1 stimulates cell migration and binds to the α5β1 integrin by means of its Arg-Gly-Asp sequence. Proc Natl Acad Sci U S A 1993; 90: 10553–10557
   PubMed Web of Science ®Google Scholar
• Meenakumari K J, Agarwal S, Krishna A, Pandey L K. Effects of metformin treatment on luteal phase progesterone concentration in polycystic ovary syndrome. Braz J Med Biol Res 2004; 37: 1637–1644
   PubMed Web of Science ®Google Scholar
• Atiomo W U, Bates S A, Condon J E, Shaw S, West J H, Prentice A G. The plasminogen activator system in women with polycystic ovary syndrome. Fertil Steril 1998; 69: 236–241
   PubMed Web of Science ®Google Scholar
• Sampson M, Kong C, Patel A, Unwin R, Jacobs H S. Ambulatory blood pressure profiles and plasminogen activator inhibitor (PAI-1) activity in lean women with and without the polycystic ovary syndrome. Clin Endocrinol (Oxf) 1996; 45: 623–629
   PubMed Web of Science ®Google Scholar
• Glueck C J, Wang P, Fontaine R N, Sieve-Smith L, Tracy T, Moore S K. Plasminogen activator inhibitor activity: an independent risk factor for the high miscarriage rate during pregnancy in women with polycystic ovary syndrome. Metabolism 1999; 48: 1589–1595
   PubMed Web of Science ®Google Scholar
• Gris J C, Neveu S, Mares P, Biron C, Hedon B, Schved J F. Plasma fibrinolytic activators and their inhibitors in women suffering from early recurrent abortion of unknown etiology. J Lab Clin Med 1993; 122: 606–615
   Google Scholar
• Velazquez E M, Mendoza S G, Wang P, Glueck C J. Metformin therapy is associated with a decrease in plasma plasminogen activator inhibitor-1, lipoprotein(a), and immunoreactive insulin levels in patients with the polycystic ovary syndrome. Metabolism 1997; 46: 454–457
   PubMed Web of Science ®Google Scholar
• Grant P J. Beneficial effects of metformin on haemostasis and vascular function in man. Diabetes Metab 2003; 29: 6S44–6S52
   PubMed Web of Science ®Google Scholar
• Morin-Papunen L, Rautio K, Ruokonen A, Hedberg P, Puukka M, Tapanainen J S. Metformin reduces serum C-reactive protein levels in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003; 88: 4649–4654
   PubMed Web of Science ®Google Scholar
• Glueck C J, Wang P, Goldenberg N, Sieve L. Pregnancy loss, polycystic ovary syndrome, thrombophilia, hypofibrinolysis, enoxaparin, metformin. Clin Appl Thromb Hemost 2004; 10: 323–334
   PubMed Web of Science ®Google Scholar
• Tarkun I, Arslan B C, Canturk Z, Turemen E, Sahin T, Duman C. Endothelial dysfunction in young women with polycystic ovary syndrome: relationship with insulin resistance and low-grade chronic inflammation. J Clin Endocrinol Metab 2004; 89: 5592–5596
   PubMed Web of Science ®Google Scholar
• Kravariti M, Naka K K, Kalantaridou S N, Kazakos N, Katsouras C S, Makrigiannakis A, Paraskevaidis E A, Chrousos G P, Tsatsoulis A, Michalis L K. Predictors of endothelial dysfunction in young women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005; 90: 5088–5095
   PubMed Web of Science ®Google Scholar
• Diamanti-Kandarakis E, Alexandraki K, Protogerou A, Piperi C, Papamichael C, Aessopos A, Lekakis J, Mavrikakis M. Metformin administration improves endothelial function in women with polycystic ovary syndrome. Eur J Endocrinol 2005; 152: 749–756
   PubMed Web of Science ®Google Scholar
• Diamanti-Kandarakis E, Paterakis T, Alexandraki K, Piperi C, Aessopos A, Katsikis I, Katsilambros N, Kreatsas G, Panidis D. Indices of low-grade chronic inflammation in polycystic ovary syndrome and the beneficial effect of metformin. Hum Reprod 2006; 21: 1426–1431
   PubMed Web of Science ®Google Scholar
• Caballero A E, Delgado A, Aguilar-Salinas C A, Herrera A N, Castillo J L, Cabrera T, Gomez-Perez F J, Rull J A. The differential effects of metformin on markers of endothelial activation and inflammation in subjects with impaired glucose tolerance: a placebo-controlled, randomized clinical trial. J Clin Endocrinol Metab 2004; 89: 3943–3948
   PubMed Web of Science ®Google Scholar
• Orio F, Jr, Palomba S, Cascella T, De Simone B, Manguso F, Savastano S, Russo T, Tolino A, Zullo F, Lombardi G, et al. Improvement in endothelial structure and function after metformin treatment in young normal-weight women with polycystic ovary syndrome: results of a 6-month study. J Clin Endocrinol Metab 2005; 90: 6072–6076
   PubMed Web of Science ®Google Scholar
• Turner M J, Walsh J, Byrne K M, Murphy C, Langan H, Farah N. Outcome of clinical pregnancies after ovulation induction using metformin. J Obstet Gynaecol 2006; 26: 233–235
   Google Scholar
• Glueck C J, Wang P, Goldenberg N, Sieve-Smith L. Pregnancy outcomes among women with polycystic ovary syndrome treated with metformin. Hum Repord 2002; 17: 2858–2864
   PubMed Web of Science ®Google Scholar